2022
An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLOS ONE 2022, 17: e0269772. PMID: 35709149, PMCID: PMC9202921, DOI: 10.1371/journal.pone.0269772.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSerotonin-norepinephrine reuptake inhibitorsUse of antipsychoticsLong-term riskAnxiety disordersReuptake inhibitorsUmbrella reviewSide effectsPanic disorderSystematic reviewNon-antipsychotic medicationsUse of quetiapineFirst-line treatmentSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsEvidence of efficacyCommon psychiatric disordersTraditional pharmacologic treatmentTreatment of anxietyAdjunctive treatmentPharmacologic treatmentTricyclic antidepressantsAntipsychoticsPsychiatric disordersSocial anxiety disorder
2021
Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, Radhakrishnan R, Slaby A, Sumner CR. Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough? Journal Of Psychiatric Practice 2021, 27: 361-371. PMID: 34529602, DOI: 10.1097/pra.0000000000000578.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsLong-term SSRI useSSRI useEase of titrationFirst-line medicationSerotonin reuptake inhibitorsRisk-benefit ratioMajor depressive disorderGeneral health risksShort-term useClinical practice considerationsDiscontinuation syndromeReuptake inhibitorsSafety profileDepressive disorderPatientsPsychiatric conditionsRelapse preventionMedicationsPossible adverse consequencesSpecial populationsAnxiety disordersTolerabilityPrescribersAdverse consequences
2020
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers In Psychiatry 2020, 11: 595584. PMID: 33424664, PMCID: PMC7786299, DOI: 10.3389/fpsyt.2020.595584.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsPosttraumatic stress disorderAnxiety disordersGABAergic medicationsReuptake inhibitorsRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialPanic disorderStress disorderSpecific phobiaBeta-adrenergic medicationsPlacebo-controlled trialCurrent pharmacological treatmentsNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCause of disabilityPrevalent psychiatric disordersNovel pharmacotherapeutic agentsBeta-adrenergic agentsSocial anxiety disorderMixed antidepressantsGlutamate modulatorsGlutamatergic agentsObsessive-compulsive disorder
2014
Advances in Psychopharmacology for Anxiety Disorders
Garakani A, Murrough J, Iosifescu D. Advances in Psychopharmacology for Anxiety Disorders. FOCUS The Journal Of Lifelong Learning In Psychiatry 2014, 12: 152-162. DOI: 10.1176/appi.focus.12.2.152.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsPosttraumatic stress disorderAnxiety disordersReuptake inhibitorsRelated conditionsGamma-aminobutyric acid (GABA) systemPharmacological treatment modalitiesFirst-line treatmentSerotonin reuptake inhibitorsNew pharmacotherapeutic approachesNorepinephrine reuptake inhibitorsVasopressin receptor antagonistsNovel treatment optionsPrevalent psychiatric disordersGlutamate modulatorsMedication classesCertain anxiety disordersNeuropeptide YTreatment modalitiesTreatment optionsNew drug developmentReceptor antagonistNew medicationsPharmacotherapeutic approaches